BioDelivery Sciences International Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioDelivery Sciences International stock.
View analyst ratings for BioDelivery Sciences International or view top-rated stocks.

Wall Street analysts have given BioDelivery Sciences International a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioDelivery Sciences International wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for BioDelivery Sciences International.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings data on Thursday, May, 6th. The specialty pharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.07 by $0.02. The specialty pharmaceutical company had revenue of $41.02 million for the quarter, compared to analysts' expectations of $40.99 million. BioDelivery Sciences International had a net margin of 16.32% and a trailing twelve-month return on equity of 26.13%.
View BioDelivery Sciences International's earnings history.

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BDSI shares have decreased by 7.8% and is now trading at $3.65.
View which stocks have been most impacted by COVID-19.

BioDelivery Sciences International issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $170 million-$180 million, compared to the consensus revenue estimate of $179.53 million.

2 brokers have issued 12-month price targets for BioDelivery Sciences International's shares. Their forecasts range from $5.50 to $6.25. On average, they expect BioDelivery Sciences International's share price to reach $5.88 in the next twelve months. This suggests a possible upside of 61.0% from the stock's current price.
View analysts' price targets for BioDelivery Sciences International or view top-rated stocks among Wall Street analysts.

Some companies that are related to BioDelivery Sciences International include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all of BDSI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), JD.com (JD), Baidu (BIDU), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

BioDelivery Sciences International's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.52%), Wasatch Advisors Inc. (5.57%), Systematic Financial Management LP (3.46%), Goldman Sachs Group Inc. (2.83%), HealthInvest Partners AB (1.98%) and Royce & Associates LP (1.91%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Jeffrey Allen Bailey, Kevin Kotler, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, Thomas B Smith and W Mark Watson.
View institutional ownership trends for BioDelivery Sciences International.

BDSI stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Nuveen Asset Management LLC, Millennium Management LLC, Renaissance Technologies LLC, D. E. Shaw & Co. Inc., Los Angeles Capital Management LLC, Man Group plc, and Zebra Capital Management LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include James Vollins, Jeffrey Allen Bailey, Mark A Sirgo, Mary Theresa Coelho, and W Mark Watson.
View insider buying and selling activity for BioDelivery Sciences International or view top insider-selling stocks.

BDSI stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, Goldman Sachs Group Inc., Wasatch Advisors Inc., Brown Advisory Inc., Hillsdale Investment Management Inc., HealthInvest Partners AB, BlackRock Inc., and Stanley Laman Group Ltd..
View insider buying and selling activity for BioDelivery Sciences International or or view top insider-buying stocks.

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BDSI stock can currently be purchased for approximately $3.65.

BioDelivery Sciences International has a market capitalization of $359.72 million and generates $156.47 million in revenue each year. The specialty pharmaceutical company earns $25.71 million in net income (profit) each year or $0.24 on an earnings per share basis.

BioDelivery Sciences International employs 176 workers across the globe.

The official website for BioDelivery Sciences International is www.bdsi.com.

BioDelivery Sciences International is headquartered at 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612.

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]